Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Oncothyreon's Shares Pushed Higher in November

By George Budwell – Dec 8, 2015 at 3:11PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Oncothyreon's shares rallied last month ahead of the company's forthcoming clinical update for its experimental breast cancer drug ONT-380.

Source: Pixabay

What: Shares of Oncothyreon (NASDAQ: ONTY), a clinical-stage biotech developing therapies to treat cancer, rose by more than 9% in November, according to data provided by S&P Capital IQ. The catalyst driving the biotech's shares higher for the month was the announcement that the company would be providing a clinical update for its experimental HER2-positive breast cancer treatment, ONT-380, at the San Antonio Breast Cancer Symposium being held from Dec. 8-12 in San Antonio, TX. ONT-380 is a small molecule inhibitor of HER2 invented by Array BioPharma (ARRY) and licensed to Oncothyreon under a broad manufacturing and commercialization agreement. 

ONTY Chart

So what: Oncothyreon is currently assessing ONT-380 as a potential treatment for advanced breast cancer in a handful of early stage studies when used in combination with Herceptin and Kadcyla.

Although ONT-380 is probably a couple of years away from an actual regulatory filing, it does offer an exciting value proposition for investors, given that the HER2 positive breast cancer drug market is expected to grow to around $8 billion by 2023, according to the research firm GlobalData. In light of Oncothyreon's current market cap of only $308 million, ONT-380 wouldn't need to grab much of this monstrous market to be a huge value driver for the company -- even when factoring in the double-digit royalties that would need to be paid to Array BioPharma if the drug is approved.

Now what: Oncothyreon is in the middle of deciding how best to proceed toward a regulatory filing for ONT-380. Per management's recent comments, the current plan is to first evaluate the results of ONT-380's early stage trial in combination with Kadcyla, and then consider approaching regulators about the best path forward. Fortunately, investors should gain some insight into the drug's clinical progress this week. Until then, however, I'm personally content to watch this small-cap biotech from the sidelines. 

George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.